In another COVID development, the FDA pulled its EUA for Evusheld, the last available monoclonal antibody treatment, due to weak activity against the newer circulating subvariants.
Flu continues hasty retreat in US; COVID, RSV markers fall
Published in COVID-19
More from COVID-19More posts in COVID-19 »
- FDA warns of false results from Cue Health COVID tests
- COVID patient testing, isolation of sick staff cut in-hospital viral spread, modeling study suggests
- TB-COVID co-infections increasingly common, tied to worse outcomes, data show
- Data: Heart-failure patients have 82% better odds of living longer if vaccinated against COVID